Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANTERN: Larotrectinib and RAI in NTRK Fusion Thyroid Cancer
NCT05783323Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Feb 2024
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of larotrectinib in differentiated thyroid cancer (DTC), sponsored by Children's Hospital of Philadelphia. Started Feb 2024; status: recruiting.
02
Drugs
larotrectinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05783323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783323.